Follow
Richard Nixon
Richard Nixon
Modeler, Novartis
Verified email at novartis.com
Title
Cited by
Cited by
Year
Asia after Viet Nam
RM Nixon
Foreign Aff. 46, 111, 1967
6751967
Relative benefit-risk comparing diclofenac to other traditional non-steroidal anti-inflammatory drugs and cyclooxygenase-2 inhibitors in patients with osteoarthritis or …
A van Walsem, S Pandhi, RM Nixon, P Guyot, A Karabis, RA Moore
Arthritis research & therapy 17, 1-18, 2015
2002015
Non‐parametric methods for cost‐effectiveness analysis: the central limit theorem and the bootstrap compared
RM Nixon, D Wonderling, RD Grieve
Health economics 19 (3), 316-333, 2010
1942010
Using mixed treatment comparisons and meta‐regression to perform indirect comparisons to estimate the efficacy of biologic treatments in rheumatoid arthritis
RM Nixon, N Bansback, A Brennan
Statistics in medicine 26 (6), 1237-1254, 2007
1872007
The effect of disease, functional status, and relapses on the utility of people with multiple sclerosis in the UK
M Orme, J Kerrigan, D Tyas, N Russell, R Nixon
Value in health 10 (1), 54-60, 2007
1842007
Developing appropriate methods for cost-effectiveness analysis of cluster randomized trials
M Gomes, ESW Ng, R Grieve, R Nixon, J Carpenter, SG Thompson
Medical Decision Making 32 (2), 350-361, 2012
1542012
Methods for incorporating covariate adjustment, subgroup analysis and between‐centre differences into cost‐effectiveness evaluations
RM Nixon, SG Thompson
Health economics 14 (12), 1217-1229, 2005
1492005
Modelling the cost effectiveness of TNF-α antagonists in the management of rheumatoid arthritis: results from the British Society for Rheumatology Biologics Registry
A Brennan, N Bansback, R Nixon, J Madan, M Harrison, K Watson, ...
Rheumatology 46 (8), 1345-1354, 2007
1452007
The efficacy of inhibiting tumour necrosis factor α and interleukin 1 in patients with rheumatoid arthritis: a meta-analysis and adjusted indirect comparisons
R Nixon, N Bansback, A Brennan
Oxford University Press 46 (7), 1140-1147, 2007
1382007
Valsartan vs. other angiotensin II receptor blockers in the treatment of hypertension: a meta‐analytical approach
RM Nixon, E Müller, A Lowy, H Falvey
International journal of clinical practice 63 (5), 766-775, 2009
1362009
Biologic drugs for rheumatoid arthritis in the Medicare program: a cost‐effectiveness analysis
AJ Wailoo, N Bansback, A Brennan, K Michaud, RM Nixon, F Wolfe
Arthritis & Rheumatism 58 (4), 939-946, 2008
1292008
Indicators of undernutrition in cattle
S Agenäs, MF Heath, RM Nixon, JM Wilkinson, CJC Phillips
Animal Welfare 15 (2), 149-160, 2006
1242006
Parametric modelling of cost data in medical studies
RM Nixon, SG Thompson
Statistics in medicine 23 (8), 1311-1331, 2004
1202004
Parametric modelling of cost data: some simulation evidence
A Briggs, R Nixon, S Dixon, S Thompson
Health economics 14 (4), 421-428, 2005
1162005
Longer polyglutamine tracts in the androgen receptor are associated with moderate to severe undermasculinized genitalia in XY males
HN Lim, H Chen, S McBride, AM Dunning, RM Nixon, IA Hughes, ...
Human Molecular Genetics 9 (5), 829-834, 2000
1102000
No evidence of disease activity: indirect comparisons of oral therapies for the treatment of relapsing–remitting multiple sclerosis
R Nixon, N Bergvall, D Tomic, N Sfikas, G Cutter, G Giovannoni
Advances in therapy 31, 1134-1154, 2014
1092014
Costs and quality of life of multiple sclerosis in the United Kingdom
G Kobelt, J Berg, P Lindgren, J Kerrigan, N Russell, R Nixon
The European Journal of Health Economics 7, 96-104, 2006
1062006
How sensitive are cost-effectiveness analyses to choice of parametric distributions?
SG Thompson, RM Nixon
Medical Decision Making 25 (4), 416-423, 2005
1022005
Using multilevel models for assessing the variability of multinational resource use and cost data
R Grieve, R Nixon, SG Thompson, C Normand
Health economics 14 (2), 185-196, 2005
912005
Bio-pics: a life in pictures
E Cheshire
Columbia University Press, 2014
862014
The system can't perform the operation now. Try again later.
Articles 1–20